Ga68-PSMA or Prostate Specific Membrane Antigen PET-CT of is now available in private for the accurate staging and re-staging of prostate cancer to determine whether of not the cancer has metastasized or spread to the skeleton and other sites. This becomes especially useful in patients with high-risk prostate cancer.
This imaging modality helps the treating oncologist and/or urologist make important clinical decisions on treatment and further management.
Tc99m-iPSMA whole body SPECT-CT has been available at TheraMed Nuclear from August 2017 and has really brought about much change in the management of these patients.
We are therefore very excited about the PET-CT tracer and can now offer both studies to suit both clinical and diagnostic needs.
Each modality has different benefits – each tailored to the referring doctors needs. Please feel free to contact us should you have any inquiries regarding either study and its performance.
For more information:
SPECT-CT Tc99m-iPSMA – August 2017
Joint EANM and SNMMI procedure guideline for prostate cancer imaging
Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
